Relay Therapeutics, Inc. Common Stock (RLAY) is a publicly traded Healthcare sector company. As of September 1, 2026, RLAY trades at $18.50 with a market cap of $4.03B and a P/E ratio of -11.90. RLAY moved +0.60% today. Year to date, RLAY is +126.04%; over the trailing twelve months it is +405.19%. Its 52-week range spans $1.78 to $21.27. Analyst consensus is strong buy with an average price target of $27.63. Rallies surfaces RLAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for RLAY, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $18.50 |
| Market Cap | $4.03B |
| P/E Ratio | -11.90 |
| EPS | $-1.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.27 |
| 52-Week Low | $1.78 |
| Volume | 834.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $10.35M |
| Net Income | $-286.04M |
| Gross Margin | 0.00% |
9 analysts cover RLAY: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.63.